Helomics

About:

Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.

Website: http://www.helomics.com/

Twitter/X: Helomics_

Top Investors: Bain Capital, HealthCare Royalty Partners, Skyline Medical Inc., Longitude Capital, Stephens

Description:

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Total Funding Amount:

$211M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Pittsburgh, Pennsylvania, United States

Founded Date:

1995-01-01

Contact Email:

info(AT)precisiontherapeutics.com

Founders:

Paul L. Kornblith

Number of Employees:

51-100

Last Funding Date:

2017-12-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai